US equities |
NVDA $237.39 ▲+1.47% MU $1,058.85 ▼-1.49% SPCX $164.28 ▲+3.35% MSFT $528.83 ▲+2.18% TSLA $374.47 ▲+1.05% INTC $116.59 ▼-2.30% SNDK $1,722.58 ▲+0.15% AMD $630.47 ▼-0.54%
FinancialContent

Articles published by Evelo Biosciences, Inc.

News headline image
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Closes $25.5 Million Private Placement
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Announces $25.5 Million Private Placement
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Announces Reverse Stock Split Effective
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Provides Clinical Updates
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Provides Clinical and Business Updates
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO HRZN
News headline image
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO
News headline image
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
From Evelo Biosciences, Inc.
Via GlobeNewswire
Tickers EVLO